“`html
Intellia Therapeutics (NTLA) shares surged 29.8% on October 16, 2023, after announcing the completion of enrollment in the Phase III HAELO study for its investigational candidate, lonvoguran ziclumeran (lonvo-z), aimed at treating hereditary angioedema (HAE). The pivotal study, which assesses the drug’s safety and efficacy in adults with type I or II HAE, achieved full enrollment within nine months of initiating patient dosing in January 2025.
Top-line data from the HAELO study is expected in the first half of 2026, with a potential biologics license application submission planned for the second half of 2026. If approved, Intellia aims to launch lonvo-z in the United States in the first half of 2027.
“`
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
